Shingles Vaccine Recommendation for Adults ≥50 Years
Adults aged 50 years and older should receive the recombinant zoster vaccine (RZV/Shingrix) as a 2-dose series administered intramuscularly 2-6 months apart, with RZV strongly preferred over the live-attenuated vaccine (ZVL/Zostavax). 1
Recommended Vaccine and Dosing
RZV (Shingrix) is the preferred vaccine based on superior efficacy and durability compared to ZVL. The standard dosing schedule is:
- Two 0.5 mL intramuscular injections
- Interval: 2-6 months between doses (minimum 4 weeks acceptable; repeat if given too soon) 1
- For immunocompromised patients, the interval may be shortened to 1-2 months 2
The evidence strongly supports RZV preference. RZV demonstrates 97.2% efficacy in preventing herpes zoster in adults ≥50 years (ZOE-50 trial) and 91.3% efficacy in those ≥70 years with 88.8% efficacy against postherpetic neuralgia (PHN) 3. This vastly outperforms ZVL, which shows only 51.3% efficacy for HZ and 66.5% for PHN in adults ≥60 years, with efficacy declining to just 18% in those ≥80 years 3.
Protection durability also favors RZV: efficacy remains above 83% for 8 years and 73% at 10 years 3, whereas ZVL efficacy drops from 51.3% to 21.2% during 7-11 years post-vaccination 3.
Special Populations
Immunocompromised Adults (≥18 years)
RZV is recommended for adults ≥19 years who are or will be immunocompromised due to disease or therapy 4. Ideally, administer the first dose at least 14 days before starting immunosuppressive treatment 2.
Previous Vaccination History
- Prior ZVL recipients: Administer RZV at least 2 months after ZVL 1
- Prior herpes zoster infection: Still vaccinate with RZV 1
Contraindications and Precautions
Absolute contraindications:
- Severe allergic reaction to any vaccine component
- Pregnancy (for ZVL; RZV should be delayed until after pregnancy if otherwise indicated) 1
Important distinction: Unlike ZVL, RZV is NOT contraindicated in immunocompromised patients because it is a non-live recombinant vaccine 2, 4. This represents a major advantage, as ZVL is contraindicated in severe immunocompromising conditions and HIV with CD4 <200 cells/μL 1.
Safety Profile
Common adverse events with RZV (significantly higher than placebo but acceptable):
- Injection site pain (22.5% of reports) 5
- Grade 3 injection site reactions: 9.5% vs 0.4% placebo 3
- Systemic symptoms (fever, myalgia, fatigue, headache): 11.4% vs 2.4% placebo 3
- Serious adverse events and deaths: No difference from placebo 3, 5
Approximately 85% of vaccinees report local or systemic reactions, with 17% experiencing grade 3 reactions that may interfere with normal activity 5. However, these are transient and do not represent safety concerns.
Clinical Pitfalls
Tolerability concerns significantly impact vaccine uptake: Individuals concerned about side effects are 1.22 times more likely to refuse vaccination and 1.83 times more likely to receive only one dose instead of completing the series 6. Proactive counseling about expected transient reactions is essential to prevent series non-completion.
Provider knowledge gaps exist: Only 29% of primary care providers are fully aware of current ACIP recommendations 7, which may contribute to suboptimal vaccination rates, particularly in the 50-59 age group where uptake is lower than in older adults 7.
Cost and access barriers: Out-of-pocket costs and lack of patient motivation represent key administration challenges 7.